Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production

Infection and Immunity

Volumn 65, Issue 8, 1997, Pages 3225-3230

  Li, Jian ^a   Sutterwala, Shaheen ^a   Farrell, Jay P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT GAMMA INTERFERON; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALING; HELPER CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS;

EID: 0030859053     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.8.3225-3230.1997     Document Type: Article

References (40)

1. Belosevic, M., D. S. Finbloom, P. H. Van Der Meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HcN mice to infection with Leishmania major. J. Immunol. 143:266-274.
2. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4. and interleukin-10. Ann. N.Y. Acad. Sci. 685:713-739.
3. Bogdan, C., Y. Vodovotz, J. Paik, and Q. W. Xie. 1994. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J. Leukocyte Biol. 55:227-233.
4. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539-542.
5. Carvalho, E. M., O. Bacellar, C. Brownell, T. Regis, R. L. Coffman, and S. G. Reed. 1994. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152:5949-5956.
6. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson. 1985. Absence of gamma Interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066-2069.
7. Carvalho, E. M., R. S. Teixeira, and W. D. Johnson, Jr. 1981. Cell mediated immunity in American visceral leishmaniasis; reversible immunosuppression during acute infection. Infect. Immun. 33:498-502.
8. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182-1187.
9. Convit, J., M. Ulrich, C. T. Fernandez, F. J. Tapia, G. Caceres-Dittmar, M. Castes, and A. J. Rondon. 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 87:444-448.
10. Curry, R. C., P. A. Kiener, and G. L. Spitalny. 1987. A sensitive immunochemical assay for biologically active MuIFN-garnma. J. Immunol. Methods 104:137-142.
11. Gazzinelli, R. T., S. Heiny, T. A. Wynn, S. Wolf, and A. Sher. 1993. Interleukin-12 is required for the T-lymphocyte-independenl induction of interferon-γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA 90:6115-6119.
12. Harms, G., K. Zwingenberger, B. Sandkamp, S. Omena, C. Pedrosa, J. Richter, F. Rosenkaimer, H. Feldmeier, and U. Bienzle. 1993. Immunochemolherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony. J. Interferon Res. 13:39-41.
13. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 169:59-72.
14. + lymphocytes in vivo during healing and progressive murine leishmaniasis, Proc. Natl. Acad. Sci. USA 88:7011-7015.
15. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin-12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505-1509.
16. Kemp, M., A. S. Hey, J. A. L. Kurtzhals, C. B. V. Christensen, A. Gaafar, M. D. Mustafa, A. A. Y. Kordofani, A. Ismail, A. Kharazmi, and T. G. Theander. 1994. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin. Exp. Immunol. 96:410-415.
17. Li, J., P. Scott, and J. P. Farrell. 1996. In vivo alterations in cytokine production following interleukin-12 (IL-12) and anti-IL-4 antibody treatment of CB6F1 mice with chronic cutaneous leishmaniasis. Infect. Immun. 64:5248-5254.
18. Ma, X., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by Interferon gamma in monocytic cells. J. Exp. Med. 183:147-157.
19. Murray, H. W., J. Hariprashad, B. Aguero, T. Arakawa, and H. Yeganegi. 1995. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J. Infect. Dis. 171:1309-1316.
20. Murray, H. W., B. V. Rubin, and C. D. Rothermel. 1983. Killing of intracellular Leishmania donovani by lymphokine-stimnlated human mononuclear phagocytes. Evidence that Interferon-γ is the activating lymphokine. J. Clin. Invest. 72:1506-1510.
21. Nabors, G. S., L. C. C. Afonso, J. P. Farrell, and P. Scott. 1994. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92:3142-3146.
22. Nabors, G. S., and J. P. Farrell. 1994, Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect. Immun. 62:5498- 5504.
23. Nabors, G. S., and J. P. Farrell. 1995. Activity of Pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-γ antibody. Am. J. Trop. Med. Hyg. 53:55-60.
24. Nabors, G. S., and J. P. Farrell. 1996. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. J. Infect. Dis. 173:979-986.
25. Nabors, G. S., T. Nolan, W. Croop, J. Li, and J. P. Farrell. 1995. The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c X C57BL/6) F1 mice infected with Leishmania major. Parasite Immunol. 17:569-579.
26. Sacks, D. L., S. Heiny, and A. Sher. 1985. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J. Immunol. 135: 564-569.
27. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma- independent mechanism. J. Exp. Med. 171:115-125.
28. Scott, P., P. Natovitz, R. L. Coffman, E. Pearce, and A. Sher. 1988. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168:1675-1684.
29. Stenger, S., H. Thuring, M. Rollinghoff, and C. Bogdan. 1994. Tissue expression of inducible nitric oxide synthase is closely associated with resis tance to Leishmania major. J. Exp. Med. 180:783-793.
30. Sundar, S., and H. W. Murray. 1995. Effect of treatment with interferon- gamma alone in visceral leishmaniasis. J. Infect. Dis. 172:1627-1629.
31. Sundar, S., F. Rosenkaimer, M. L. Lesser, and H. W. Murray. 1995. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J. Infect. Dis. 171:992-996
32. Sundar, S., F. Rosenkaimer, and H. W. Murray. 1994. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon- gamma. J. Infect. Dis. 170:659-662.
33. Sypek, J. P., C. L. Chung, S. E. H. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797-1802.
34. Titus, R. G., R. Ceredig, J. C. Cerrottini, and J. Louis. 1985. Therapeutic effect of anti-L3T4 monoclonal GK1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice. J. Immunol. 135:2108-2114.
35. Trinchieri, G. 1995. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
36. van Lunzen, J., P. Kern, J. Schmitz, J. Brzoska, S. Flessenkamper, and M. Dietrich. 1993. Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and pentavalent antimony. Infection 21:362-366.
37. Vodovotz, Y., C. Bogdan, J. Paik, Q.-W. Xie, and C. Nathan. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J. Exp. Med. 178:605-613.
38. Wang, Z.-E., S. L. Reiner, S. Zheng, D. K. Dalton, and R. M. Locksley. 1994 CD4+ effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367-1371.
39. Wynn, T. A., I. Eltoum, A. W. Cheever, F. A. Lewis, W. C. Gause, and A. Sher 1993. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151:1430-1440.
40. Zwingenberger, K., G. Harms, C. Pedrosa, S. Omena, B. Sandkamp, and S. Neifer. 1990. Determinants of the immune response to visceral leishmaniasis evidence for the predominance of endogenous interleukin 4 over interferon-γ production. Clin. Immunol. Pathol. 57:242-249.